Qianglian Zhichuang (Beijing) Technology

Established in September 2016 by founder and chairwoman Qin嵐, Qianglian Zhichuang (Beijing) Technology Co., Ltd. is a high-tech enterprise focused on developing intelligent diagnosis and treatment solutions for cerebrovascular diseases. The company's inception was driven by the significant challenges and high skill requirements of neuro-interventional surgery for conditions like brain aneurysms. Recognizing the lack of a comprehensive Chinese cerebrovascular disease database, Qin岚 led her team to build one from the ground up by collaborating with national neurological hospitals, which now underpins their product development.

The company's business is centered on applying artificial intelligence to improve the entire workflow of cerebrovascular disease management, from screening and diagnosis to treatment and follow-up. Its target market includes not only the top-tier hospitals in major cities but also a vast network of thousands of local and community-level hospitals where advanced surgical expertise may be less accessible. The business model involves providing integrated solutions that combine software, hardware, and associated medical consumables. A significant milestone was achieved in October 2022, when its "Intracranial Aneurysm Surgical Planning Software" received NMPA approval as an innovative medical device. The firm has successfully secured multiple rounds of funding, including a Series C round led by Sequoia China in January 2022 and a D+ round in 2024, to facilitate its transition from research and development to commercialization and market expansion.

Qianglian Zhichuang's core offering is an AI-driven, integrated solution for intracranial aneurysm surgery. This platform includes the UKnow® Intracranial Aneurysm Surgical Planning Software, which assists surgeons by rendering 3D images from patient scans (DSA, CTA, MRA), allowing for precise measurement and visualization of the aneurysm. A key benefit of the software is its ability to help plan the micro-catheter's path and shape for delivering coils, which can increase the first-pass success rate, shorten procedure times, and reduce radiation exposure for both doctor and patient. This AI-powered system aims to standardize and simplify complex surgical procedures, shortening the learning curve for less experienced surgeons. The full solution comprises the intelligent software, an automated hardware terminal (UMate™), and related consumables, creating a comprehensive system that assists surgeons from pre-operative planning to critical surgical steps.

Keywords: cerebrovascular disease, medical AI, neuro-interventional surgery, intracranial aneurysm, surgical planning software, intelligent diagnosis, medical imaging, digital therapeutics, AI-assisted surgery, NMPA approval, Qin嵐, stroke treatment, medical device, health technology, AI-powered healthcare, surgical robotics, clinical decision support, 3D medical visualization, catheter path planning, embolization assistance, healthcare solutions provider